There is a persistent gap between preclinical promise and clinical reality in oncology drug development. Two-dimensional cell culture systems derived from animal models cannot reproduce the architectural and microenvironmental complexity that shapes therapeutic responses in human tumours. Poor clinical outcomes despite encouraging preclinical data have prompted regulatory agencies to emphasise human-relevant test systems, with reduced reliance on animal models to improve translational accuracy.